Six studies were included in the review (n=404): two RCTs (n=225) and four prospective studies (n=179). Both RCTs had a Jadad score of 3.
Albendazole was associated with significantly better control of seizures than praziquantel (OR 4.94, 95% CI 2.45 to 9.98, p<0.00001; one RCT and three prospective studies, n=156) and total disappearance of cysts (OR 2.30, 95% CI 1.06 to 5.00, p=0.03; six studies, n=335) than praziquantel. There was strong evidence of statistical heterogeneity for both analyses (I2=51.2% and 50.3%, Χ2 p=0.07).
There was no significant difference between drugs for reduction of cysts, adverse events or intracranial hypertension. The authors reported that mortality data was inadequate to allow meaningful analysis.